CA2578956A1 - Combination comprising zd6474 and an imatinib - Google Patents

Combination comprising zd6474 and an imatinib Download PDF

Info

Publication number
CA2578956A1
CA2578956A1 CA002578956A CA2578956A CA2578956A1 CA 2578956 A1 CA2578956 A1 CA 2578956A1 CA 002578956 A CA002578956 A CA 002578956A CA 2578956 A CA2578956 A CA 2578956A CA 2578956 A1 CA2578956 A1 CA 2578956A1
Authority
CA
Canada
Prior art keywords
imatinib
pharmaceutically acceptable
warm
human
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002578956A
Other languages
English (en)
French (fr)
Inventor
Stephen Robert Wedge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0421438A external-priority patent/GB0421438D0/en
Priority claimed from GB0506726A external-priority patent/GB0506726D0/en
Application filed by Individual filed Critical Individual
Publication of CA2578956A1 publication Critical patent/CA2578956A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002578956A 2004-09-27 2005-09-23 Combination comprising zd6474 and an imatinib Abandoned CA2578956A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0421438A GB0421438D0 (en) 2004-09-27 2004-09-27 Combination therapy
GB0421438.3 2004-09-27
GB0506726.9 2005-04-01
GB0506726A GB0506726D0 (en) 2005-04-01 2005-04-01 Combination therapy
PCT/GB2005/003673 WO2006035204A2 (en) 2004-09-27 2005-09-23 Combination comprising zd6474 and an imatinib

Publications (1)

Publication Number Publication Date
CA2578956A1 true CA2578956A1 (en) 2006-04-06

Family

ID=35924044

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002578956A Abandoned CA2578956A1 (en) 2004-09-27 2005-09-23 Combination comprising zd6474 and an imatinib

Country Status (11)

Country Link
US (2) US20080119479A1 (enExample)
EP (1) EP1804802A2 (enExample)
JP (1) JP2008514577A (enExample)
KR (1) KR20070072543A (enExample)
AU (1) AU2005288737B2 (enExample)
BR (1) BRPI0516052A (enExample)
CA (1) CA2578956A1 (enExample)
IL (1) IL181609A0 (enExample)
MX (1) MX2007003505A (enExample)
NO (1) NO20071428L (enExample)
WO (1) WO2006035204A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
CA2514227C (en) * 2003-02-13 2011-08-09 Astrazeneca Ab Combination therapy of zd6474 with 5-fu or/and cpt-11
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
BRPI0412426A (pt) * 2003-07-10 2006-09-05 Astrazeneca Ab uso da zd6474 ou de um sal farmaceuticamente aceitável da mesma e de um agente antitumoral de platina, composição farmacêutica, kit, e método para a produção de um efeito antiangiogênico e/ou redutor de permeabilidade vascular em um animal de sangue quente
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
EP1971338B8 (en) * 2005-12-22 2011-09-21 AstraZeneca AB Combination of zd6474 and pemetrexed
US20100092466A1 (en) * 2006-09-29 2010-04-15 Anderson Joseph Ryan Combination of zd6474 and bevacizumab for cancer therapy
EP3352107B1 (en) 2008-03-03 2025-10-22 NIKE Innovate C.V. Interactive athletic equipment system
US8172722B2 (en) 2008-12-05 2012-05-08 Nike, Inc. Athletic performance monitoring systems and methods in a team sports environment
US8231506B2 (en) 2008-12-05 2012-07-31 Nike, Inc. Athletic performance monitoring systems and methods in a team sports environment
US8628453B2 (en) 2008-12-05 2014-01-14 Nike, Inc. Athletic performance monitoring systems and methods in a team sports environment
EP4138095A1 (en) 2010-11-10 2023-02-22 Nike Innovate C.V. Systems and methods for time-based athletic activity measurement and display
JP5782529B2 (ja) 2011-02-17 2015-09-24 ナイキ イノベイト シーブイ 身体活動データの選択および画像データとの関連付け
KR101386697B1 (ko) * 2012-06-18 2014-04-18 아주대학교산학협력단 이매티닙 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 혈관 투과성 관련 질환의 치료 또는 예방용 조성물
AU2014296032A1 (en) 2013-07-31 2016-03-17 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
KR101778004B1 (ko) 2015-06-22 2017-09-15 (주) 에빅스젠 이마티닙을 유효성분으로 포함하는 안구 건조 질환 예방 및 치료용 약학 조성물
US20200206223A1 (en) 2017-07-26 2020-07-02 Ftf Pharma Private Limited Liquid dosage forms of imatinib

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1676845B1 (en) * 1999-11-05 2008-06-11 AstraZeneca AB New quinazoline derivatives
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
RU2376029C2 (ru) * 2002-04-25 2009-12-20 Юниверсити Оф Коннектикут Хелт Сентер Применение белков теплового шока для улучшения терапевтического эффекта невакцинного лечебного воздействия
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
EP1534287A1 (en) * 2002-08-09 2005-06-01 Astrazeneca AB Combination of zd6474, an inhibitor of the vascular endothelial growth factor receptor, with radiotherapy in the treatment of cancer
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
CA2514227C (en) * 2003-02-13 2011-08-09 Astrazeneca Ab Combination therapy of zd6474 with 5-fu or/and cpt-11
BRPI0412426A (pt) * 2003-07-10 2006-09-05 Astrazeneca Ab uso da zd6474 ou de um sal farmaceuticamente aceitável da mesma e de um agente antitumoral de platina, composição farmacêutica, kit, e método para a produção de um efeito antiangiogênico e/ou redutor de permeabilidade vascular em um animal de sangue quente
JP2008514576A (ja) * 2004-09-27 2008-05-08 アストラゼネカ アクチボラグ Ａｚｄ２１７１およびイマチニブを含む癌組合せ療法
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
EP1971338B8 (en) * 2005-12-22 2011-09-21 AstraZeneca AB Combination of zd6474 and pemetrexed

Also Published As

Publication number Publication date
US20080119479A1 (en) 2008-05-22
JP2008514577A (ja) 2008-05-08
MX2007003505A (es) 2007-05-10
BRPI0516052A (pt) 2008-08-19
WO2006035204A2 (en) 2006-04-06
AU2005288737A1 (en) 2006-04-06
KR20070072543A (ko) 2007-07-04
IL181609A0 (en) 2007-07-04
NO20071428L (no) 2007-04-02
US20100069398A1 (en) 2010-03-18
AU2005288737B2 (en) 2008-08-14
WO2006035204A3 (en) 2006-10-19
EP1804802A2 (en) 2007-07-11

Similar Documents

Publication Publication Date Title
CA2531862C (en) Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
US20100069398A1 (en) Combination therapy
US20090325977A1 (en) Cancer combination therapy comprising azd2171 and imatinib
US20110212978A1 (en) Combination of ZD6474 and Pemetrexed
EP1965801B1 (en) Combination of azd2171 and pemetrexed
EP1729807B1 (en) Combination therapy with azd-2171
HK1123976B (en) Combination of azd2171 and pemetrexed
HK1123186B (en) Combination of zd6474 and pemetrexed
HK1089378B (en) Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
ZA200600186B (en) Use of the quinazoline derivative ZD6474 combined with platinum compounds and optionally ionising radiation in the treatment of deseases associated with angiogenesis and/or increased vascular permeability

Legal Events

Date Code Title Description
FZDE Discontinued